LUCID DIAGNOSTICS INC
LUCDNASDAQTrading Snapshot
- Day Range
- $0.38 – $0.44
- 52-Week Range
- $0.30 – $1.63
- Volume (shares)
- 6,254,213
- Avg Volume (shares)
- —
- Shares Outstanding
- 190.9M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 16.4x
- EPS (TTM)
- $-0.38
- Dividend Yield
- —
- Dilution (1yr)
- +76.7%
LUCID DIAGNOSTICS INC
LUCD
StockOtter · stockotter.spaceAbout LUCID DIAGNOSTICS INC
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term shareholders strengthens L
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell col
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
Lucid Diagnostics NASDAQ: LUCD is positioning its EsoGuard test as a non-invasive tool to identify Barrett's Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a key Medicare coverage
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laborat
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
Lucid Diagnostics Q2 Earnings Call Highlights
Lucid Diagnostics NASDAQ: LUCD reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while awaiting a Medicare d